Sandoz management has set out more details of how it intends to reposition in the US market the Cimerli (ranibizumab-eqrn) biosimilar to Lucentis that it licenses from Formycon.
Sandoz Suggests Coherus’ Cimerli Strategy Was ‘Unsustainable’
Expands On Plans To Withdraw And Reintroduce US Lucentis Biosimilar
In the wake of Formycon’s recent announcement that US marketing partner Sandoz would be pausing commercialization of the Cimerli rival to Lucentis that it recently took over from Coherus, Sandoz management has offered a few more details on its plans for the ranibizumab biosimilar.
More from Biosimilars
More from Business
• By
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
• By
With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.
• By
The divestment marks a further step in Fresenius’ ongoing strategy towards a more optimized and simplified company structure while doubling down on new endeavors in the Biopharma space.